Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
What makes computation possible in brains?
Nima Dehghani formalizes how computation can arise out of physical systems, such as brains, and describes the “special sauce” for real biological agency.
What makes computation possible in brains?
Nima Dehghani formalizes how computation can arise out of physical systems, such as brains, and describes the “special sauce” for real biological agency.
Fish brains follow swimming friends to avoid foes
A subset of neurons in glassfish activate when the animals see others escape, new research shows, offering clues for how collective behaviors emerge from individual neural activity.
Fish brains follow swimming friends to avoid foes
A subset of neurons in glassfish activate when the animals see others escape, new research shows, offering clues for how collective behaviors emerge from individual neural activity.
Scaling up n-of-1 trials; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 16 November.
Scaling up n-of-1 trials; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 16 November.